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Background on QIV-HD Vaccine Development
• TIV-HD is a high dose, inactivated trivalent influenza vaccine that has been 
available in the US since 2010. 
 115 million doses sold since licensure 
 2 out of 3 vaccinated adults 65+ years of age in the US received Fluzone HD vaccine 
during the 2018-2019 season (~22 million doses)
• Two distinct B influenza lineages (Victoria and Yamagata) have co-circulated 
for over a decade, making it difficult to predict which will predominate the next 
season.  
• QIV-HD has been developed to address the frequent influenza B strain 
mismatches by incorporating a strain from each B lineage.
• QHD00013 is a pivotal Phase III study which evaluated the safety and 
immunogenicity of QIV-HD as compared to TIV-HD.
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High Dose Studies Overview
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Meta-analysis and Systemic Review of TIV-HD 
Efficacy/Effectiveness versus SD Vaccine
Over 14 million adults received TIV-HD in the studies.
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Outcome
RCT and Observational Studies RCT Studies only (4 trials) 
rVE (95%CI) p-value rVE (95%CI) p-value
Influenza-like Illness 15.9%(4.1% - 26.3%) 0.01
24.1% 
(10.0–36.1)
0.002
Influenza Hospitalization 12.6% (7.1% - 17.9%) <0.001 Not assessed
Pneumonia Hospitalization 27.3% (15.3% - 37.6%) <0.001
27.3%
(15.3–37.6)
<0.001
Pneumonia/Influenza 
Hospitalization
13.4% 
(7.3% - 19.2%)
<0.001 Not assessed
Cardiorespiratory Hospitalization 17.9% (15.0% - 20.8%) <0.001
17.9% 
(15.0% - 20.8%)
<0.001
All-cause Hospitalization 8.4% (5.7% - 11.0%) <0.001
11.9%
(2.0–20.7)
0.019
Lee et al. Meta-analysis and Systemic Review. Options X for the Control of Influenza. Aug 19, 2019.
Chang et al.
Safety and Immunogenicity of High-
Dose Quadrivalent Influenza Vaccine 
(QIV-HD) Administered by 
Intramuscular Route in Subjects 
Aged 65 Years and Older
E-published ahead of print in Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
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Phase III QHD00013 Overview
• Randomized, modified double-blind, active-controlled
• Primary Objective: to demonstrate non-inferior immunogenicity (based on HAI assay 
GMTs and seroconversion rates)
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Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
QHD00013 Study Overview
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Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
Demographics: Gender, Age, and Racial Origin
The randomized groups were balanced by age, gender, and racial origin.
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(N= number of 
evaluable subjects)
QIV-HD
(N= 1680)
TIV-HD1
(N= 423)
TIV-HD2
(N= 430)
Overall
(N= 2533)
Males 703 (41.8%) 172 (40.7%) 191 (44.5%) 1066 (42.1%)
Females 977 (58.2%) 251 (59.3%) 239 (55.6%) 1467 (57.9%)
Mean age (years) 72.9 72.8 73.2 73.0
Percentage of 
subjects ≥75 yrs
of age
35.4% 33.3% 38.1% 35.5%
Caucasian 91.2% 89.8% 89.5% 90.7%
Total subjects based on the Per-Protocol Analysis Dataset (PPAS) in this table.
5.1% attrition rate seen in the study.
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
QHD00013 Safety Overview
No related deaths or related AE of special interest in all study groups.
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Subject experiencing 
at least one 
QIV-HD
(N= 1777)
TIV-HD pooled
(N= 893)
Immediate unsolicited AE 5 (0.3%) 2 (0.2%)
AE leading to study 
discontinuation 1/1777 (<0.1%) 2/893 (0.2%)
SAE (within 28 days) 19/1777 (1.1%) 12/893 (1.3%)
SAE (entire study) 80/1777 (4.5%) 48/893 (5.4%)
Fatal 3/1777 (0.2%) 2/893 (0.2%)
AE of special interest 1/1777 (<0.1%) 2/893 (0.2%)
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
Solicited Reactions Overview
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QIV-HD
TIV-HD
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
Solicited Reactions: Local and Systemic
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QIV-HD
TIV-HD
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
QHD00013: Summary of Safety Results
• While higher percentages for some solicited reactions were 
observed for QIV-HD, the overall reactogenicity profile was 
comparable to TIV-HD.
 QIV-HD and TIV-HD study groups showed similar rates of unsolicited events, 
AEs leading to study discontinuation, SAEs, fatal SAEs, and AEs of special 
interest.
• One related SAE: a subject reporting small fiber neuropathy 
diagnosed 42 days after QIV-HD vaccination with other concomitant 
etiologies (vitamin B12 deficiency and recent viral illness) 
 Our (the Sponsor) assessment was unrelated to study vaccine given the other 
more likely etiologies and symptom improvement with vitamin B12 
supplementation
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Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
GMTs: QIV-HD versus TIV-HD
QIV-HD induced  non-inferior antibody responses (GMTs) compared to TIV-HD against all 
4 vaccine strains 28 days post-vaccination.
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Ratio of GMT 0.83 0.95 1.08 1.00
Lower bound of the CI* 0.744 0.842 0.958 0.881
*Lower bound of the confidence interval (CI) should be >0.667 for non-inferiority to be reached.
QIV-HD
TIV-HD†
†TIV-HD GMTs pooled for 
the A/H1N1 and A/H3N2 
comparison. TIV-HD1 
(contains B Brisbane but 
not B Phuket) or TIV-HD2 
(contains B Phuket but not 
B Brisbane) GMTs for the 
matching B strain used for 
the B strain comparisons.
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
Seroconversion: QIV-HD versus TIV-HD
QIV-HD induced non-inferior seroconversion rates compared to TIV-HD against all 4 
vaccine strains 28 days post-vaccination.
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Difference in Seroconversion 
(QIV-HD minus TIV-HD) -3.27% -0.71% -2.41% -1.75%
Lower bound of the CI* -7.37% -4.83% -7.66% -7.04%
*Lower bound of the confidence interval (CI) should be >-10% for non-inferiority to be reached.
QIV-HD
TIV-HD†
†TIV-HD seroconversion rates 
pooled for the A/H1N1 and 
A/H3N2 comparison. TIV-HD1 
(contains B Brisbane but not B 
Phuket) or TIV-HD2 (contains 
B Phuket but not B Brisbane) 
seroconversion rates for the 
matching B strain used for the 
B strain comparisons against 
QIV-HD.
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
Secondary Endpoint: Superiority for Alternate B Strain
QIV-HD induced an immune response superior to that induced 
by the TIV-HD that did not contain the corresponding B strain.
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GMT QIV-HD TIV-HD GMT ratio(QIV-HD/TIV-HD) Lower Bound of the CI*
B/Brisbane 516 253 2.04 1.805
B/Phuket 578 282 2.05 1.806
Seroconversion QIV-HD TIV-HD Difference in SC(QIV-HD—TIV-HD) Lower Bound of the CI*
B/Brisbane 36.5% 15.2% 21.36% 17.01%
B/Phuket 46.6% 17.6% 29.04% 24.45%
*Lower bound of the confidence interval (CI) should be >1.5 for superiority to be reached with respect to GMT and >10% for 
superiority to be  reached with respect to seroconversion.
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
Overall Key Study Results
• Safety Results
– No safety issues were observed with QIV-HD in adults 65 years of age and 
older.
• Safety profiles between QIV-HD and TIV-HD were similar.
• Immunogenicity Results
– Primary Objective Met: QIV-HD was non-inferior to TIV-HD by GMTs and 
seroconversion rates for all 4 strains. 
– Secondary Objective Met: QIV-HD induced an immune response superior to 
that induced by the TIV-HD that did not contain the corresponding B strain.
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The study results demonstrated that addition of a second influenza B strain 
in QIV-HD did not impact the safety or immunogenicity of the other 3 
strains in subjects 65 years of age and older. 
Chang L-J, et al. Vaccine (Aug 2019): https://doi.org/10.1016/j.vaccine.2019.08.016
QIV-HD Next Steps
•CBER action date: November 4, 2019
•Assuming licensure: 
 HCPs will be able to pre-order QIV-HD in Q1 2020
 TIV-HD will be entirely replaced by QIV-HD for the 2020-2021 
season
18
Sanofi Pasteur’s High Dose Influenza Vaccine
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Sanofi Pasteur remains committed 
to the study of the performance of 
our influenza vaccines and their 
ability to reduce influenza and its 
associated complications across 
seasons and settings in order to 
understand the differences each 
vaccine brings.
BACK UP
QHD00013: Race and Ethnicity
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(N= number of evaluable subjects) QIV-HD(N=1680)
TIV-HD1
(N=423)
TIV-HD2
(N=430)
Overall
(N=2533)
Racial origin: n (%)
American Indian or Alaska Native 9 (0.5) 2 (0.5) 3 (0.7) 14 (0.6)
Asian 12 (0.7) 2 (0.5) 3 (0.7) 17 (0.7)
Black or African American 114 (6.8) 36 (8.5) 32 (7.4) 182 (7.2)
Native Hawaiian or other Pacific Islander 3 (0.2) 1 (0.2) 1 (0.2) 5 (0.2)
White 1532 (91.2) 380 (89.8) 385 (89.5) 2297 (90.7)
Multiple 6 (0.4) 1 (0.2) 2 (0.5) 9 (0.4)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Not reported 4 (0.2) 1 (0.2) 4 (0.9) 9 (0.4)
Ethnicity
Hispanic or Latino 47 (2.8) 9 (2.1) 13 (3.0) 69 (2.7)
Not Hispanic or Latino 1630 (97.0) 413 (97.6) 415 (96.5) 2458 (97.0)
Unknown 0 (0.0) 0 (0.0) 1 (0.2) 1 (<0.1)
Not reported 3 (0.2) 1 (0.2) 1 (0.2) 5 (0.2)
QHD00013: Solicited Reactions 
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Most frequently reported reactions: injection site pain and myalgia
Solicited reactions within 7 days after vaccine injection (Safety Analysis Set)
Visual Example: Relative Efficacy Translates to Absolute Efficacy
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Vaccinate with SD
Vaccinate with HD
How 24% Relative Efficacy Translates to Absolute Efficacy
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Absolute Efficacy of SD vaccine Relative Efficacy of HD vaccine Absolute Efficacy of HD vaccine
10%
24% relative efficacy
32%
20% 39%
30% 47%
40% 54%
50% 62%
60% 70%
70% 77%
80% 85%
Efficacy Results of HD vs SD Fluzone Vaccine in a 
Randomized Clinical Trial
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Compared to standard-dose (SD), the benefit of high-dose (HD) was demonstrated across age groups, 
influenza types, comorbidities, and frailty-associated conditions in 32,000 community-dwelling seniors
*against laboratory-confirmed influenza illness caused by any virus type or subtype in adults 65 years of age and older
References: 1,2DiazGranados CA et al. N Engl J Med 2014;371(7):635-645.
3DiazGranados CA et al. 2015 Vaccine;33(36):4565-4571. 
PRIMARY ENDPOINT Similar to Vaccine Strains1 Year 13 Year 23
24.2%
more efficacious*
HD (N=228) vs. SD (N=301)
(95% CI: 9.7; 36.5)
35.4%
(95% CI: 12.5; 52.5)
45.3%
(95% CI: 6.9; 68.6)
20.7%
(95% CI: 4.4; 34.3)
65-74 Years of Age2 75+ Years of Age2
19.7%
(95% CI: 0.4; 35.4)
32.4%
(95% CI: 8.1; 50.6)
Demonstrated SUPERIOR 
EFFICACY against primary 
endpoint compared to IIV3-SD1
≥1 High-Risk Comorbidity2 1 Frailty-Associated Condition2
22.1%
(95% CI: 3.9; 37.0)
27.5%
(95% CI: 0.4; 47.4)
